

Recent Publications: year 2004

27 original publications

1. Drewe M, Drewe J, Riecher-Rössler A: Cannabis and the risk of psychosis. *Swiss Med Wkly* 134: 659–663(2004)
2. Drewe J. Lipids and Glaucoma. *In: Shaarawy T, Flammer J. Glaucoma Therapy. Current Issues and Controversies.* Martin Dunitz. London - New York 2004, pp 61 - 68.
3. Fischer LM, Schlienger RG, Matter C, Jick H, Meier CR. Effect of rheumatoid arthritis or systemic lupus erythematosus on the risk of First-Time acute myocardial infarction. *Am J Cardiol.* 93(2): 198-200 (2004).
4. Fischer LM, Schlienger RG, Matter CM, Jick H, Meuer CR. Discontinuation of Nonsteroidal Anti-inflammatory Drug Therapy and Risk of Acute Myocardial Infarction *Arch Intern Med* 2004;164:2472-2476.
5. Giostra E, Kullak-Ublick GA, Keller W, Fried R, Vanlemmens C, Krähenbühl S, Locher S, Egger HP, Clavien PA, Hadengue A, Mentha G, Morel P, Negro F. Ribavirin/interferon-alpha sequential treatment of recurrent hepatitis C after liver transplantation. *Transpl Int.* 2004;17:169-76.
6. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, Gutmann H, Drewe J, Henzen C, Goeke B, Beglinger C: Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. *J Clin Endocrinol Metab* 89: 3055-3061 (2004).
7. Heuss LT, Drewe J, Schnieper P, Tapparelli CB, Pflimlin E, Beglinger C. Patient-controlled versus nurse-administered sedation with propofol during colonoscopy. A prospective randomized trial. *Am J Gastroenterol.* 2004 Mar;99(3):511-8.
8. Krähenbühl S. Pharmakokinetische Prinzipien und Dosisanpassung. *In: Medizinische Therapie in Klinik und Praxis.* Ed.: J. Schölmerich. *Springer-Verlag.* 2004;in press.
9. Krähenbühl S. Adverse effects and drug-drug interactions. *In: Pharmacotherapy of obesity.* Hofbauer KG, Keller U, Boss O, editors. *CRC Press.* 2004;285-296.
10. Krähenbühl S. Dosisangleichung bei Niereninsuffizienz und Nierenersatzverfahren. *Eur J Hosp Pharmacy* 2004;10:24-27
11. Krähenbühl S. Toxische Leberschäden. *Therapeutische Umschau* 2004;61:529-534.
12. Krähenbühl S. Pharmakokinetik und –dynamik im Alter. *Schweiz Rundsch Med Prax* 2004;93:1305-1310.

13. Meier CR, Wilcock K and Jick SS. The Risk of Severe Depression, Psychosis or Panic Attacks with Prophylactic Antimalarials. *Drug Safety* 2004; 27 (3): 203-213
14. Rätz Bravo AE, Egger SS, Crespo S, Probst WL, Krähenbühl S. Lithium intoxication as a result of an interaction with rofecoxib. *Ann Pharmacother.* 2004 Jul-Aug;38(7-8):1189-93
15. Roten L, Schoenenberger RA, Krähenbühl S, Schlienger RG. Rhabdomyolysis in association with simvastatin and amiodarone. *Ann Pharmacother* 38(6):978-81. Epub 2004 Apr 06 (2004)
16. Sieber CC, Beglinger C, Bart S, Tschoepf M, Currie G, Larsen F, Drewe J. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion. *Clin Pharmacol Ther* 75: 70-79 (2004)
17. Schächinger H, Dieterle T, Martina B, Haberthür C, Huber PR, Bock A, Drewe J, Gyr K. Increased renovascular response to angiotensin II in persons genetically predisposed to arterial hypertension disappears after chronic ACE inhibition. *J Hypertension* 22:175–180 (2004)
18. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation : can they prevent acute myocardial infarction? *Am J Cardiovasc Drugs.* 2003;3(3):149-62.
19. Schlienger RG, Kraenzlin ME, Jick S, Meier CR. Use of beta-blockers and the risk of bone fractures. *JAMA* 2004;292:1326-32.
20. Schlienger RG, Jick SS, Meier CR. Inhaled corticosteroids and the risk of fractures in children and adolescents. *Pediatrics.* 2004 Aug;114(2):469-73
21. Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. *Drug Saf.* 2004;27(14):1157-65.
22. Schnyder A, Krähenbühl S, Török M, Drewe J, Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. *Biochem J.* 377:61-7 (2004)
23. Vernez L, Wenk M, Krähenbühl S. Determination of carnitine and acylcarnitines in plasma by high-performance liquid chromatography/electrospray ionization ion trap tandem mass spectrometry. *Rapid Commun Mass Spectrom.* 2004;18(11):1233-8
24. Wenk M, Todesco L, Krähenbühl S. Effect of St John's wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. *Br J Clin Pharmacol* 47: 495-499 (2004)
25. Wenk M, Drewe J, Krähenbühl S. Abteilung für Klinische Pharmakologie & Toxikologie am Universitätsspital Basel. In : Philippu A, editor. Geschichte und Wirken der pharmakologischen, klinisch-pharmakologischen und toxikologischen Institute im deutschsprachigen Raum. Berenkamp. 2004;40-46.

26. Zimmermann C, Gutmann H, Hruz P, Gutzwiller J-P, Beglinger C, Drewe J. Mapping of MDR1 and MRP1-5 mRNA expression along the human intestinal tract. *Drug Metab Disposition* (2004)
27. Zimmermann C, J. Drewe, J. Flammer and T. Shaarawy: In vitro release of mitomycin C from collagen implants. *Current Eye Res* 28: 1-4 (2004)